Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/120599
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Short duration response-guided treatment is effective for most individuals with recent hepatitis C infection: The ATAHC II and DARE-C i studies
Author: Martinello, M.
Hellard, M.
Shaw, D.
Petoumenos, K.
Applegate, T.
Grebely, J.
Yeung, B.
Maire, L.
Iser, D.
Lloyd, A.
Thompson, A.
Sasadeusz, J.
Haber, P.
Dore, G.
Matthews, G.
Citation: Antiviral Therapy, 2016; 21(5):425-434
Publisher: International Medical Press
Issue Date: 2016
ISSN: 1359-6535
2040-2058
Statement of
Responsibility: 
Marianne Martinello, Margaret Hellard, David Shaw, Kathy Petoumenos, Tanya Applegate, Jason Grebely, Barbara Yeung, Laurence Maire, David Iser, Andrew Lloyd, Alexander Thompson, Joe Sasadeusz, Paul Haber, Gregory J Dore, Gail V Matthews
Abstract: Individuals with recent HCV infection may benefit from shortened duration therapy. These studies evaluated the efficacy and safety of response-guided regimens with pegylated interferon-α2a and ribavirin for people with recent HCV infection.Participants with recent hepatitis C (duration of infection ≤18 months) enrolled in the ATAHC II (pegylated interferon-α2a ± ribavirin) and DARE-C I (pegylated interferon-α2a, ribavirin and telaprevir) studies were included for analysis. Treatment duration was response-guided (ATAHC II: 8, 16, 24 or 48 weeks; DARE-C I: 8, 12 or 24 weeks) and dependent on time to first undetectable HCV RNA using Roche Taqman HCV RNA testing. The primary efficacy end point was sustained virological response at 12 weeks (SVR12) by intention-to-treat. Logistic regression analyses were used to identify predictors of SVR.A total of 82 participants (62% HIV-positive) were enrolled in ATAHC II (treated, n=52) and 14 (79% HIV-positive) in DARE-C I. The predominant modes of HCV acquisition were injecting drug use (ATAHC II 55%, DARE-C I 36%) and sexual intercourse with a partner of the same sex (ATAHC II 39%, DARE-C I 64%). SVR12 was 71% in both ATAHC II (37/52) and DARE-C I (10/14) with 56% in ATAHC II receiving shortened therapy (8 or 16 weeks). SVR was associated with a rapid virological response (odds ratio 10.80; P=0.001).The majority of participants were able to receive short duration response-guided therapy with pegylated interferon-α2a and ribavirin. Response-guided therapy for recent hepatitis C infection could be considered in the absence of available interferon-free therapies. ClinicalTrials.gov registry (ATAHC II: NCT01336010; DARE-C I: NCT01743521).
Keywords: Humans; Hepatitis C; Hepatitis C, Chronic; Polyethylene Glycols; Oligopeptides; Interferon-alpha; Recombinant Proteins; RNA, Viral; Ribavirin; Antiviral Agents; Treatment Failure; Drug Therapy, Combination; Drug Administration Schedule; Prospective Studies; Time Factors; Adult; Middle Aged; Female; Male; Medication Adherence
Rights: Copyright (c) 2016 International Medical Press, all rights reserved.
RMID: 0030123115
DOI: 10.3851/IMP3035
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.